Author’s response to reviews

Title: Clinical Characteristics and Mutation Spectrum of Neurofibromin 1 in 12 Chinese Families with Orbital/Periorbital Plexiform Neurofibromatosis Type 1

Authors:

Peiwei Chai (chaipeiwei123@sjtu.edu.cn)
Yingxiu Luo (yxluo1124@sjtu.edu.cn)
Chuandi Zhou (smile_mapletree@sjtu.edu.cn)
Yefei Wang (paper34@163.com)
Xianqun Fan (fanxq@sjtu.edu.cn)
Renbing Jia (renbingjia@sjtu.edu.cn)

Version: 4 Date: 15 Aug 2019

Author’s response to reviews:

1. We have revised the consent to participate statement in the “Ethical approval and consent to participate” section of your manuscript from “Written consent was obtained for all involved patients.” to “Written, informed consent was obtained for all involved patients.”

2. We have clarified that “Written, informed consent was obtained for all involved patients. A form letter containing the carrier screening agreement for children younger than 18 years old was signed by their parents” in Consent to publish section.

3. We have revised “availability of data and materials” section to “The raw sequencing data have been uploaded as supplementary files. The datasets analysed during the current study are available in the ClinVAR database (https://www.ncbi.nlm.nih.gov/clinvar/, accession number: VCV000638015, VCV000635821, VCV000635820, VCV000635819, VCV000635818 and VCV000186215).”

4. We have revised “Authors’ contributions” section to “XQF, RBJ and YFW conceived and designed the study; PWC and CDZ was responsible for patient data; YFW and YXL presented during data collection; YXL and PWC performed the study in the laboratory; YFW and RBJ conducted data analyses; PWC wrote the first draft, and it reviewed by RBJ and XQF. All authors read and approved the final manuscript.”

5. We have revised “s Table1” to “Supplementary Table 1”.

6. A single, final, clean version has been uploaded